Swedish Orphan Biovitrum AB SOBI

STO: SOBI | ISIN: SE0000872095 8/07/2025

285,00 SEK (-0,35%)

(-0,35%) 8/07/2025

Grafiek Swedish Orphan Biovitrum AB

Grafiek Swedish Orphan Biovitrum AB

1 dag1d -0,35%
1 week1w -0,14%
1 maand1m -7,17%
3 maanden3m 15,57%
6 maanden6m -10,94%
1 jaar1j 1,14%
5 jaar5j 35,46%

woensdag 16 juli 2025, 08:00

Kwartaalcijfers (2de kwartaal)

Swedish Orphan Biovitrum AB in het nieuws

Toon enkel gratis nieuws

8 mei 2025 · Bulletin from Sobi's Annual General Meeting (AGM) · Persbericht

29 april 2025 · Sobi publishes Q1 2025 report: Portfolio continues to deliver · Persbericht

1 april 2025 · Notice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ) · Persbericht

31 maart 2025 · Sobi publishes Annual and sustainability report for 2024 · Persbericht

29 augustus 2024 · Sobi has completed issues of class C shares · Persbericht

8 augustus 2024 · Sobi and Apellis announce positive topline results from phase 3 VALIANT study of pegcetacoplan in C3G and primary IC-MPGN · Persbericht

16 juli 2024 · Sobi Q2 2024 report: Strong delivery driven by robust portfolio performance · Persbericht

15 juli 2024 · The Board of Directors of Sobi exercises authorisation for repurchase of shares for the purpose of securing the company's commitments under incentive programmes · Persbericht

2 juli 2024 · Sobi initiates rolling biologics license application to FDA for SEL-212 for the potential treatment of chronic refractory gout · Persbericht

19 juni 2024 · European Commission grants Sobi® Marketing Authorisation for ALTUVOCT™ for treatment of haemophilia A · Persbericht

Profiel Swedish Orphan Biovitrum AB

CEO: Guido Oelkers

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe